

# Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/TA459CD82B3EN.html>

Date: April 2018

Pages: 49

Price: US\$ 3,500.00 (Single User License)

ID: TA459CD82B3EN

## Abstracts

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H1 2018

### SUMMARY

According to the recently published report 'Type 2 Angiotensin II Receptor - Pipeline Review, H1 2018'; Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult.

Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

The report 'Type 2 Angiotensin II Receptor - Pipeline Review, H1 2018' outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Oncology, Women's Health and Respiratory which include indications Polycystic Ovarian Syndrome, Acute Ischemic Stroke, Atherosclerosis, Cardiomyopathy, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Dementia Associated With Alzheimer's Disease, Dermatitis, Diabetic Nephropathy, Diabetic Neuropathic Pain, Hyperlipidemia, Hypertension, Idiopathic Pulmonary Fibrosis, Inflammation, Inflammatory Pain, Kidney Fibrosis, Leiomyosarcoma, Liver Fibrosis, Multiple Sclerosis, Myocardial Fibrosis, Myocardial Infarction, Neuromyelitis Optica (Devic's Syndrome), Non-Alcoholic Steatohepatitis (NASH), Obesity, Peripheral Neuropathic Pain, Postherpetic Neuralgia, Prostate Cancer, Psoriasis, Pulmonary Arterial Hypertension, Rheumatoid Arthritis, Skin Inflammation, Spinal Cord Injury, Systemic Sclerosis (Scleroderma) and Type 2 Diabetes.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -

Companies Involved in Therapeutics Development

CJ HealthCare Corp

MorphoSys AG

Novartis AG

Vicore Pharma AB

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles

(amlodipine besylate + valsartan)+ atorvastatin calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-6A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olodanrigan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and  
Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant  
Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) -  
Discontinued Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product  
Development Milestones

Featured News & Press Releases

Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis

Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor

Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for  
Idiopathic Pulmonary Fibrosis

Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications

Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid  
metabolism with C21

Aug 17, 2017: Results from Extension Study with C21 Show Safety, Tolerability and  
Indicate Effects on lipid Metabolism

May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with  
Lanthipeptide MOR107 in Healthy Volunteers

Mar 08, 2017: C21 has a strong impact on several markers in an in vitro study for

pulmonary fibrosis

Mar 03, 2017: New positive study results on diabetic nephropathy with Vicore Pharma's candidate drug C21

Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107

Feb 15, 2017: Vicore Pharma extends research portfolio with new drug molecules

Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D.

Appointed Chief Medical Officer (CMO) of MorphoSys's Dutch Lanthipeptide Subsidiary

Aug 01, 2016: Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF

Jun 30, 2016: New research data with C21 on diabetes

Jun 15, 2016: Prestigious award for UQ superstar scientist

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indications, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by CJ HealthCare Corp, H1 2018  
Pipeline by MorphoSys AG, H1 2018  
Pipeline by Novartis AG, H1 2018  
Pipeline by Vicore Pharma AB, H1 2018  
Dormant Projects, H1 2018  
Discontinued Products, H1 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

CJ HealthCare Corp

MorphoSys AG

Novartis AG

Vicore Pharma AB

## I would like to order

Product name: Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/TA459CD82B3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TA459CD82B3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

